Jeremy S. Abramson

18.9k total citations · 2 hit papers
237 papers, 5.5k citations indexed

About

Jeremy S. Abramson is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Jeremy S. Abramson has authored 237 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Oncology, 118 papers in Pathology and Forensic Medicine and 64 papers in Genetics. Recurrent topics in Jeremy S. Abramson's work include Lymphoma Diagnosis and Treatment (118 papers), CAR-T cell therapy research (95 papers) and Chronic Lymphocytic Leukemia Research (61 papers). Jeremy S. Abramson is often cited by papers focused on Lymphoma Diagnosis and Treatment (118 papers), CAR-T cell therapy research (95 papers) and Chronic Lymphocytic Leukemia Research (61 papers). Jeremy S. Abramson collaborates with scholars based in United States, Switzerland and France. Jeremy S. Abramson's co-authors include Margaret A. Shipp, Ephraim P. Hochberg, Jeffrey A. Barnes, Aliyah R. Sohani, Jon Arnason, Christiana E. Toomey, Matthew A. Lunning, Jacob D. Soumerai, Ann S. LaCasce and Tanya Siddiqi and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Jeremy S. Abramson

218 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The AP1-dependent secretion of galectin-1 by Reed–Sternberg cells fosters immune privilege in classical Hodgkin lymphoma

2007 263 citations Jeremy S. Abramson et al. profile →
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

2022 186 citations Jeremy S. Abramson, Scott R. Solomon et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeremy S. Abramson United States	40	3.3k	2.6k	1.2k	1.0k	1.0k	237	5.5k
John Kuruvilla Canada	34	4.4k 1.4×	3.8k 1.4×	1.5k 1.2×	994 1.0×	1.4k 1.4×	295	7.1k
Leslie Popplewell United States	34	2.8k 0.8×	2.0k 0.8×	751 0.6×	1.1k 1.1×	1.1k 1.1×	202	5.0k
Matthew A. Lunning United States	29	2.0k 0.6×	1.6k 0.6×	592 0.5×	679 0.7×	700 0.7×	163	3.4k
Nicola Gökbuget Germany	49	3.8k 1.2×	1.8k 0.7×	1.1k 0.9×	1.3k 1.3×	963 1.0×	179	9.1k
Michael A. Pulsipher United States	47	2.4k 0.7×	902 0.3×	1.3k 1.1×	1.1k 1.1×	1.5k 1.5×	253	7.6k
Stephen J. Schuster United States	48	8.3k 2.5×	4.7k 1.8×	2.0k 1.7×	1.7k 1.7×	2.9k 2.9×	366	11.7k
Ephraim P. Hochberg United States	42	1.9k 0.6×	2.0k 0.8×	1.2k 1.0×	619 0.6×	987 1.0×	148	5.2k
Marco Bregni Italy	45	4.7k 1.4×	3.0k 1.1×	1.6k 1.4×	2.0k 2.0×	2.4k 2.4×	193	10.0k
Anthony S. Stein United States	43	2.9k 0.9×	873 0.3×	934 0.8×	1.5k 1.5×	1.2k 1.2×	242	6.8k
Peter Borchmann Germany	45	3.5k 1.1×	4.5k 1.7×	1.0k 0.9×	930 0.9×	1.6k 1.6×	305	7.1k

Countries citing papers authored by Jeremy S. Abramson

Since Specialization

Citations

This map shows the geographic impact of Jeremy S. Abramson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeremy S. Abramson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeremy S. Abramson more than expected).

Fields of papers citing papers by Jeremy S. Abramson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeremy S. Abramson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeremy S. Abramson. The network helps show where Jeremy S. Abramson may publish in the future.

Co-authorship network of co-authors of Jeremy S. Abramson

This figure shows the co-authorship network connecting the top 25 collaborators of Jeremy S. Abramson. A scholar is included among the top collaborators of Jeremy S. Abramson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeremy S. Abramson. Jeremy S. Abramson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hunter, Bradley D., Matthew A. Lunning, Sairah Ahmed, et al.. (2025). CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting. Transplantation and Cellular Therapy. 32(2). 171.e1–171.e12. 1 indexed citations

Abramson, Jeremy S., et al.. (2024). Management of peripheral neuropathy associated with brentuximab vedotin in the frontline treatment of classical Hodgkin lymphoma. Critical Reviews in Oncology/Hematology. 204. 104499–104499.

Schett, Georg, Tatyana Feldman, Jeremy S. Abramson, et al.. (2024). P105 NEX-T CD19 chimeric antigen receptor (CAR) T-cell therapy CC-97540 (BMS-986353): Preclinical and translational evidence of deep B-cell depletion suitable for study in severe refractory autoimmune diseases. SHILAP Revista de lepidopterología. A115–A116. 2 indexed citations

Abramson, Jeremy S., et al.. (2023). Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma. Blood Advances. 8(2). 484–496. 12 indexed citations

Karmali, Reem, Jeremy S. Abramson, Deborah M. Stephens, et al.. (2023). Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma. Blood Advances. 7(23). 7361–7368. 3 indexed citations

Ababneh, Hazim, Andrea K. Ng, Matthew J. Frigault, et al.. (2023). Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy. Haematologica. 108(11). 2972–2981. 9 indexed citations

Ryan, Christine E., Danielle M. Brander, Paul M. Barr, et al.. (2023). A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia. Leukemia. 37(4). 835–842. 2 indexed citations

Baird, John H., Pim Mutsaers, Jeremy S. Abramson, et al.. (2023). Abstract CT129: Trial in progress: ATHENA-1 - a phase 1, open-label, first-in-human study to assess safety and tolerability of REGN5837 in combination with odronextamab in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphomas. Cancer Research. 83(8_Supplement). CT129–CT129. 2 indexed citations

Nastoupil, Loretta J., Manali Kamdar, Julio C. Chávez, et al.. (2023). LISOCABTAGENE MARALEUCEL (LISO‐CEL) VERSUS STANDARD OF CARE (SOC) AS SECOND‐LINE THERAPY IN LARGE B‐CELL LYMPHOMA (TRANSFORM STUDY): SUBGROUP ANALYSES BY PRIOR THERAPY RESPONSE. Hematological Oncology. 41(S2). 212–214.

10.

Supko, Jeffrey G., Michael B. Maris, Ian W. Flinn, et al.. (2022). A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma. Cancer Research Communications. 2(8). 795–805. 23 indexed citations

11.

Abramson, Jeremy S., Scott R. Solomon, Jon Arnason, et al.. (2022). Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor T Cell Therapy, Compared with Standard of Care (SOC) Using Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study. Transplantation and Cellular Therapy. 28(3). S188–S189.

12.

Solomon, Scott R., Amitkumar Mehta, Jeremy S. Abramson, et al.. (2021). Experience of Prior Anti-CD19 Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Non-Hodgkin Lymphoma (B-NHL) Receiving Lisocabtagene Maraleucel (liso-cel), an Investigational Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Product. Transplantation and Cellular Therapy. 27(3). S207–S208. 3 indexed citations

13.

Frigault, Matthew J., Jörg Dietrich, María Martínez-Lage, et al.. (2019). Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 134(11). 860–866. 160 indexed citations

14.

Abramson, Jeremy S., Maria Lia Palomba, Leo I. Gordon, et al.. (2019). Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas. Blood. 134(Supplement_1). 241–241. 89 indexed citations

15.

Lampson, Benjamin L., Haesook T. Kim, Matthew S. Davids, et al.. (2017). Efficacy Results of a Phase 2 Trial Evaluating Idelalisib Plus Ofatumumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia. Blood. 130. 1734–1734. 4 indexed citations

16.

Siddiqi, Tanya, Jeremy S. Abramson, D. Li, et al.. (2017). Patient Characteristics and Pre-Infusion Biomarkers of Inflammation Correlate with Clinical Outcomes after Treatment with the Defined Composition, CD19-Targeted CAR T Cell Product, JCAR017. Blood. 130. 193–193. 14 indexed citations

17.

Abramson, Jeremy S., Maria Lia Palomba, Leo I. Gordon, et al.. (2017). High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort. Blood. 130. 581–581. 54 indexed citations

18.

Lampson, Benjamin L., Siddha Kasar, Tiago R. Matos, et al.. (2016). Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 128(2). 195–203. 227 indexed citations

19.

Canellos, George P., Jeremy S. Abramson, David C. Fisher, & Ann S. LaCasce. (2010). Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma With Chemotherapy Without Consolidation by Radiation Therapy. Journal of Clinical Oncology. 28(9). 1611–1615. 39 indexed citations

20.

Abramson, Jeremy S., et al.. (1977). Needle aspiration biopsy of the pancreas at laparotomy.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 68(1). 30–3. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact